A Good Year for CAR-T Therapies

Seven chimeric antigen receptor (CAR) T-cell therapies to help patients’ immune systems fight cancer were approved by the FDA in 2024. They include the novel therapy obecabtagene autoleucel, or obe-cel (Aucatzyl, Autolus), and six approvals for expanded indications for three other products.